Hormonal effects of orally administered LCI699 were examined in rat and monkey in vivo models of adrenocorticotropic hormone (ACTH) and angiotensin-II-stimulated aldosterone release, and were compared with the mineralocorticoid receptor antagonist eplerenone in a randomized, placebo-controlled study conducted in 99 healthy human subjects. The effects of LCI699 and eplerenone on cardiac and renal sequelae of aldosterone excess were investigated in a double-transgenic rat (dTG rat) model overexpressing human renin and angiotensinogen. In healthy human subjects, LCI699 0.5 mg selectively reduced plasma and 24 h urinary aldosterone by 49 ± 3% and 39 ± 6% respectively (Day 1, mean ± SEM; P < 0.001 vs placebo), which was associated with natriuresis and an increase in plasma renin activity. Doses of LCI699 greater than 1 mg inhibited basal and ACTH-stimulated cortisol. Eplerenone 100 mg increased plasma and 24 h urinary aldosterone while stimulating natriuresis and increasing renin activity. In contrast to eplerenone, LCI699 increased the aldosterone precursor 11-deoxycorticosterone and urinary potassium excretion.
Authors: Joël Ménard, Dean F Rigel, Catherine Watson, Arco Y Jeng, Fumin Fu, Michael Beil, Jing Liu, Wei Chen, Chii-Whei Hu, Jennifer Leung-Chu, Daniel LaSala, Guiqing Liang, Sam Rebello, Yiming Zhang, William P Dole
Keywords: cytochrome P-450 CYP11B2, imidazoles, pyridines
DOI Number: 10.1186/s12967-014-0340-9 Publication Year: 2014
To search for other research papers by topic, keyword, author, or year, please go to our Publications page.